Navigation Links
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
Date:9/23/2013

Atlanta, September 23, 2013 A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total androgen suppression (TAS).

The multi-institutional phase III trial, Radiation Therapy Oncology Group (RTOG) 9910, evaluated 1,490 intermediate-risk prostate cancer (PCa) patients from 152 institutions in the U.S. and Canada. Patients were accrued from 2000 to 2004 and followed for an average of 9 years, and the average age of the men was 71 at the time of accrual. The patients were stratified and randomized into two groups―Group 1 consisted of 752 patients who received eight weeks of NEO TAS, and Group 2 consisted of 738 patients who received 28 weeks of NEO TAS. Both groups then received eight weeks of external beam radiation therapy (RT) and concurrent TAS.

Cumulative incidence was used to estimate and test efficacy for DSS, prostate-specific antigen (PSA) failure, locoregional tumor progression and distant metastasis. Overall survival (OS) rates were estimated via the Kaplan-Meier method and efficacy tested with log rank. There were 30 PCa deaths in Group 1, for a 10-year DSS rate of 95 percent; and 24 PCa deaths in Group 2, for a 10-year DSS rate of 96 percent (no statistical difference). There were 200 additional deaths not attributable to PCa in Group 1 for a 10-year OS rate of 66 percent, and 196 such deaths in Group 2, for a 10-year OS rate of 67 percent. By 10 years, 27 percent of patients had a PSA failure (using the newer RTOG-ASTRO definition of nadir+2), 5 percent had PCa recurrence in the prostate (locoregional) and 6 percent had distant metastasis. Hot flashes and erectile dysfunction were more common in Group 2.

"Sometimes, preliminary research leads us to assume that more treatment is better, but this study serves as a strong cautionary note to put the promising treatment to the test," said Thomas Pisansky, MD, lead author of the study and professor of radiation oncology at the Mayo Clinic in Rochester, Minn. "Overall, both groups had very, very good outcomes, but patients assigned to Group 2 had more side effects from androgen suppression than Group 1, who received only eight weeks of NEO TAS. Now, investigators know the upper boundary of how much androgen suppression is needed in this group of patients. The results have substantial importance because they can alter the research strategy to one in which investigation can now concentrate on ways to simplify the treatment and further reduce side effects."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. PeopleKeys Develops HR Filtering Tools in Response to Fewer Jobs, Increased Competition in Health Care
2. Twin Cities Home Sales Hit A Hot Summer Pace: 31.4 Percent Fewer Days
3. Longest and largest study of insulin pumps to treat type 1 diabetes in children shows they control blood sugar more effectively and with fewer complications than injections
4. Kwiksure Examines Why Drivers Have Fewer Accidents on Hong Kong Island than in the New Territories
5. Fewer states holding alcohol retailers responsible for harms from illegal service
6. Prostate cancers are fewer, smaller on walnut-enriched diet
7. Fewer Families Struggling to Pay Medical Bills: CDC
8. Healthy lifestyle choices mean fewer memory complaints, poll by UCLA and Gallup finds
9. Integrated stroke care system results in fewer deaths, discharges to long-term care facilities
10. Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup
11. Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now offering liquid ... a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. Pedram Ghasri, ... of other treatments, to rejuvenate and renew the facial appearance. , Sculptra is ...
(Date:12/7/2016)... , ... December 07, 2016 , ... They are musicians ... sisters and wives, brothers and fathers, from New England and around the nation. What ... stigma, and are brought together in a beautiful and compelling new photographic exhibit debuting ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart ... in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is ... for a brain tumor. , Jason Bauer and his family are longtime members ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who uses ... why the co-inventor and I have designed a new and better way to secure ... the patent-pending AV-AIR, a device that serves as an alternative to conventional methods of ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” reveals that ... was published in the prestigious Journal of Veterinary Science & Medical Diagnosis. , ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016 KEY FINDINGS Patient ... as reducing loss of blood during surgeries, lowering ... rapid recovery after surgeries, and decreasing risks of ... into convective warming system, surface warming systems, and ... the stay at hospitals thus, lowering the healthcare ...
(Date:12/7/2016)... RAPIDS, Mich. , Dec. 7, 2016 A ... being readied for human clinical trials in search of the ... disease following publication of research findings today in the ... "We hope this will be a watershed moment for millions ... M.D., Ph.D. , director of Van Andel Research Institute,s ...
(Date:12/7/2016)... , Dec. 7, 2016 Global ... pulmonary drugs studies the current as well as ... of this report include companies and intermediaries engaged ... drugs and/or drug-device combinations as well as new ... comprises an elaborate executive summary along with a ...
Breaking Medicine Technology: